IGM Biosciences, Inc., a biotechnology company, develops Immunoglobulin M antibodies for the treatment of cancer and autoimmune and inflammatory diseases. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California. Show more

Location: 325 East Middlefield Road, Mountain View, CA, 94043, United States | Website: https://igmbio.com | Industry: Biotechnology | Sector: Healthcare

Market Cap

77.78M

52 Wk Range

$0.92 - $22.50

Previous Close

$1.29

Open

$1.29

Volume

356,937

Day Range

$1.27 - $1.31

Enterprise Value

-26.53M

Cash

104.3M

Avg Qtr Burn

-39.13M

Insider Ownership

35.39%

Institutional Own.

50.04%

Qtr Updated

06/30/25

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Aplitabart (IGM-8444) + birinapant Details Hematologic malignancies, Solid tumor/s	Phase 1 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Aplitabart (IGM-8444) (DR5 agonist) + FOLFIRI +/- bevacizumab Details Cancer, Solid tumor/s, Colorectal cancer	Phase 1 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Aplitabart (IGM-8444) + venetoclax & azacytidine Details Acute myeloid leukemia	Phase 1 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
IGM-7354 (IL-15 x PD-L1) Details Solid tumor/s, Cancer, Hematologic malignancies	Phase 1 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Imvotamab (IGM-2323) (CD20 x CD3) Details Idiopathic inflammatory myopathy / myositis	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Imvotamab (IGM-2323) (CD20 x CD3) Details Cancer, Chronic lymphocytic leukemia, Non-Hodgkin lymphoma	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Imvotamab (IGM-2323) (CD20 x CD3) Details Systemic lupus erythematosus, Autoimmune disease	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Imvotamab (IGM-2323) (CD20 x CD3) Details Autoimmune disease, Rheumatoid arthritis	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
IGM-2644 (CD38 x CD3) Details Multiple myeloma	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
IGM-6268 Details Solid tumor/s, Cancer	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.